HCN2 and schizophrenia: INO80E has been highlighted before as a promising drug target as it is a GWAS, TWAS, and CNV hit for schizophrenia (36), while HCN2 has been identified as differentially methylated in the prefrontal cortex and hippocampus in schizophrenic patients (61, 62), and its knockdown leads to antidepressant behavior in rodents (63).